IL-33 inhibits the differentiation and immunosuppressive activity of granulocytic myeloid-derived suppressor cells in tumor-bearing mice

Immunology and Cell Biology

Volumn 95, Issue 1, 2017, Pages 99-107

  Lim, Hui Xuan ^a   Choi, Seulah ^a   Cho, Daeho ^b   Kim, Tae Sung ^a  

^a Korea University   (South Korea)

^b Sookmyung Women's University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; GAMMA INTERFERON; INTERLEUKIN 33; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW PROGENITOR CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL EXPANSION; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GRANULOCYTE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MELANOMA; MONOCYTE; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SPLEEN; SUPPRESSOR CELL; TUMOR MICROENVIRONMENT; ANIMAL; BONE MARROW CELL; C57BL MOUSE; CELL LINEAGE; CYTOLOGY; DRUG EFFECTS; EXPERIMENTAL MELANOMA; FEMALE; IMMUNOLOGY; METABOLISM; MYELOID-DERIVED SUPPRESSOR CELL; PATHOLOGY; STEM CELL;

ANIMALS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL LINEAGE; FEMALE; IMMUNOSUPPRESSION; INTERLEUKIN-33; MELANOMA, EXPERIMENTAL; MICE, INBRED C57BL; MYELOID-DERIVED SUPPRESSOR CELLS; REACTIVE OXYGEN SPECIES; STEM CELLS; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 84984804677     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2016.72     Document Type: Article

References (39)

1. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-174.
2. Youn J-I, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008; 181: 5791-5802.
3. Youn J-I, Gabrilovich DI. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 2010; 40: 2969-2975.
4. Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer 2013; 13: 739-752.
5. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23: 479-490.
6. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010; 10: 103-110.
7. Rank MA, Kobayashi T, Kozaki H, Bartemes KR, Squillace DL, Kita H. IL-33-activated dendritic cells induce an atypical TH2-type response. J Allergy Clin Immunol 2009; 123: 1047-1054.
8. Kurowska-Stolarska M, Stolarski B, Kewin P, Murphy G, Corrigan CJ, Ying S et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol 2009; 183: 6469-6477.
9. Smithgall MD, Comeau MR, Park Yoon B-R, Kaufman D, Armitage R, Smith DE. IL-33 amplifies both Th1-and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK Cells. Int Immunol 2008; 20: 1019-1030.
10. Bourgeois E, Van LP, Samson M, Diem S, Barra A, Roga S et al. The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-? production. Eur J Immunol 2009; 39: 1046-1055.
11. Bonilla WV, Fröhlich A, Senn K, Kallert S, Fernandez M, Johnson S et al. The alarmin interleukin-33 drives protective antiviral CD8+ T cell responses. Science 2012; 335: 984-989.
12. Turnquist HR, Zhao Z, Rosborough BR, Liu Q, Castellaneta A, Isse K et al. IL-33 expands suppressive CD11b+ Gr-1int and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J Immunol 2011; 187: 4598-4610.
13. Vasanthakumar A, Moro K, Xin A, Liao Y, Gloury R, Kawamoto S et al. The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue-resident regulatory T cells. Nat Immunol 2015; 16: 276-285.
14. Kurowska-Stolarska M, Kewin P, Murphy G, Russo RC, Stolarski B, Garcia CC et al. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol 2008; 181: 4780-4790.
15. Xu D, Jiang HR, Li Y, Pushparaj PN, Kurowska-Stolarska M, Leung BP et al. IL-33 exacerbates autoantibody-induced arthritis. J Immunol 2010; 184: 2620-2626.
16. Miller AM, Liew FY. The IL-33/ST2 pathway?a new therapeutic target in cardiovascular disease. Pharmacol Ther 2011; 131: 179-186.
17. Humphreys NE, Xu D, Hepworth MR, Liew FY, Grencis RK. IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J Immunol 2008; 180: 2443-2449.
18. Jovanovic I, Radosavljevic G, Mitrovic M, Juranic VL, McKenzie AN, Arsenijevic N et al. ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma. Eur J Immunol 2011; 41: 1902-1912.
19. Gao K, Li X, Zhang L, Bai L, Dong W, Gao K et al. Transgenic expression of IL-33 activates CD8(+) T cells and NK cells and inhibits tumor growth and metastasis in mice. Cancer Lett 2013; 335: 463-471.
20. Gao X,Wang X, Yang Q, Zhao X,WenW, Li G et al. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. J Immunol 2015; 194: 438-445.
21. Lim HX, Hong HJ, Cho D, Kim TS. IL-18 enhances immunosuppressive responses by promoting differentiation into monocytic myeloid-derived suppressor cells. J Immunol 2014; 193: 5453-5460.
22. Brickshawana A, Shapiro VS, Kita H, Pease LR. Lineage(-)Sca1+c-Kit(-)CD25+ cells are IL-33-responsive type 2 innate cells in the mouse bone marrow. J Immunol 2011; 187: 5795-5804.
23. Kim J, Kim W, Le HT, Moon UJ, Tran VG, Kim HJ et al. IL-33-induced hematopoietic stem and progenitor cell mobilization depends upon CCR2. J Immunol 2014; 193: 3792-3802.
24. De Santo C, Salio M, Masri SH, Lee LY-H, Dong T, Speak AO et al. Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J Clin Invest 2008; 118: 4036-4348.
25. Chatterjee S, Das S, Chakraborty P, Manna A, Chatterjee M, Choudhuri SK. Myeloid derived suppressor cells (MDSCs) can induce the generation of Th17 response from naïve CD4+ T cells. Immunobiology 2013; 218: 718-724.
26. Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006; 66: 1123-1131.
27. Pan PY, Ma G, Weber KJ, Ozao-Choy J, Wang G, Yin B et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 2010; 70: 99-108.
28. Yan D, Yang Q, Shi M, Zhong L, Wu C, Meng T et al. Polyunsaturated fatty acids promote the expansion of myeloid-derived suppressor cells by activating the JAK/STAT3 pathway. Eur J Immunol 2013; 43: 2943-2955.
29. Morales J, Kmieciak M, Knutson K, Bear H, Manjili M. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1-bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res Treat 2010; 123: 39-49.
30. Brunner SM, Schiechl G, Falk W, Schlitt HJ, Geissler EK, Fichtner-Feigl S. Interleukin-33 prolongs allograft survival during chronic cardiac rejection. Transpl Int 2011; 24: 1027-1039.
31. Gajardo T, Morales RA, Campos-Mora M, Campos-Acuna J, Pino-Lagos K. Exogenous interleukin-33 targets myeloid-derived suppressor cells and generates periphery-induced Foxp3(+) regulatory T cells in skin-transplanted mice. Immunology 2015; 146: 81-88.
32. Matta BM, Lott JM, Mathews LR, Liu Q, Rosborough BR, Blazar BR et al. IL-33 is an unconventional Alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2+ regulatory T cells. J Immunol 2014; 193: 4010-4020.
33. Ribechini E, Greifenberg V, Sandwick S, Lutz M. Subsets, expansion and activation of myeloid-derived suppressor cells. Med Microbiol Immunol 2010; 199: 273-281.
34. Kim EK, Jeon I, Seo H, Park YJ, Song B, Lee KA et al. Tumor-derived osteopontin suppresses antitumor immunity by promoting extramedullary myelopoiesis. Cancer Res 2014; 74: 6705-6716.
35. Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic MZ, Arsenijevic NN et al. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer 2014; 134: 1669-1682.
36. Xiao P, Wan X, Cui B, Liu Y, Qiu C, Rong J et al. Interleukin 33 in tumor microenvironment is crucial for the accumulation and function of myeloid-derived suppressor cells. Oncoimmunology 2016; 5: e1063772.
37. Lim HX, Hong H-J, Jung MY, Cho D, Kim TS. Principal role of IL-12p40 in the decreased Th1 and Th17 responses driven by dendritic cells of mice lacking IL-12 and IL-18. Cytokine 2013; 63: 179-186.
38. Tian J, Ma J, Ma K, Guo H, Baidoo SE, Zhang Y et al. ?-Glucan enhances antitumor immune responses by regulating differentiation and function of monocytic myeloid-derived suppressor cells. Eur J Immunol 2013; 43: 1220-1230.
39. Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P et al. HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 2010; 207: 2439-2453.